Regarding the pregnancy outcome in patients with Rheumatoid Arthritis (RA), most concerns are linked to pharmacological therapies. In order to manage the disease and obtain a favourable outcome of the pregnancy, there are several remissive or biological therapies that may be used, with minimal precautions. The anti-rheumatic drugs that may be used in RA are classified into 4 pregnancy risk categories according to the risk of inducing fetal injury: minimal risks, medium risks, high risks, and unknown risks. For many biological therapies, the lack of extensive studies is limiting the therapeutic recommendations in this sensitive area; recommendations are coming from experts in this field. However, if the preconceptual period and all the pregnancy conducts comply with the general recommendations, we may conclude that medication and pregnancy in rheumatoid arthritis may be combined with minimal risks.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً